- Majeed, M. Prakash, L, Badmaev, V., Nujoma, Y., Natarajan, S., Norton, T., Sysler, M., Gopinathan, S., and Alegesan, K (1999) Redefining Our Standards, Boswellin® The Only Natural Leukotriene and HLE Inhibitor® . Sabinsa Corporation.
- Majeed, M., Badmaev, V., Gopinathan, S., Rajendran, R., Norton, T., and Braly, J. (1996) Boswellin® The Anti-inflammatory Phytonutrient. Nutriscience Publishers Inc., Piscataway, NJ.
- Henderson, W.R. (1994) The role of leukotrienes in inflammation. Ann. Intern. Med. 121, 684-697.
- Ford Hutchinson, A.W. Gresser, M., and Young, R.N. (1993) 5-Lipoxygenase. Ann. Rev. Biochem. 63, 383-417.
- Safayhi, H., Mack, T., Sabieraj, J., Anazodo, M.I., Subramanian, L.R., and Ammon, H.P.T. (1992) Boswellic acids: Novel, specific, nonredox inhibitors of 5-lipoxygenase. J. Pharmacol. Exp. Ther. 261(3), 1143-1146.
- Sailer, E-R., Subramanian, L.R., Rall, B., Hoernlein, R.F., Ammon, H.P.T., and Safayhi, H. (1996) Acetyl-11-keto-b-boswellic acid (AKBA): structure requirements for binding and 5-lipoxygenase inhibitory activity. Br. J. Pharmacol. 117, 615-618.
- Sailer, E-R.; Schweizer, S., Boden, S.E., Ammon, H.P.T., and Safayhi, H. (1998) Characterization of acetyl-11-keto-b-boswellic acid and arachidonate-binding regulatory site of 5-lipoxygenase using photoaffinity labeling. Eur. J. Biochem. 256, 364-368.
- Aharony, D. and Stein, R.L. (1986) Kinetic mechanism of guinea pig neutrophil 5-lipoxygenase. J. Biol. Chem. 261, 11512-11519.
- Werz, O., Szellas, D., Henseler, M., and Steinhilber, D. (1998) Nonredox 5-Lipoxygenase inhibitors require glutathione peroxidase for efficient inhibition of 5-lipoxygenase activity. Molecular Pharmacology 54, 445-451.
- Lau, C.K., Belanger, P.C., Dufresne C., Scheigetz, J., Therien, M., Fitzsimmons, B., Young, R.N., Ford-Hutchinson, A.W., Riendeau, D., Denis, D., Guay, J., Charleson, S., Piechuta, H., McFarlane, C.S., Chiu, S.H.L., Eline, D., Alvaro, R.F., Miwa, G., and Walsh, J.L. (1992) Development of 2,3-dihydro-6-(3-phenoxypropyl)-2-(2-phenylethyl)-5-benzofuranol (L-670,630) as a potent and orally active inhibitor of 5-lipoxygenase. J. Med. Chem. 35, 1299-1318.
- Safayhi, H., Rall, B., Salier, E-R., and Ammon, H.P.T. (1997) Inhibition by boswellic acids of human leukocyte elastase. J. Pharmacol. Exp. Ther. 281, 460-463.
- Ellis, R.E., Yuan, J.Y., and Horvitz, H.R. (1991) Mechanisms and functions of cell death . Ann. Rev. Cell. Biol. 7, 663-698.
- Raff, M.C., Barres, B.A., Burne, J.F., Coles, H.S., Ishizaki, Y., and Jacobson, M.D. (1993) Programmed cell death and the control of cell survival: Lessons from the nervous system. Science (Washington DC) 262, 695-700.
- Rougier, P. and Bugat, R. (1996) CPT-11 in the treatment of colorectal cancer: Clinical efficacy and safety profile. Semin. Oncol. 23, 34-41.
- Anderson, K.M., Seed, T., Plate, J.M., Jajeh, A., Meng, J., and Harris, J.E. (1995) Selective inhibitors of 5-lipoxygenase reduce CML blast cell proliferation and induce limited differentiation and apoptosis. Leukotr. Res. 19, 789-801.
- Hoernlein, R.F., Orlikowsky, TH., Zehrer, C., Niethammer, D., Sailer, E.R., Simmet, TH., Dannecker, G.E., and Ammon, H.P.T. (1999) Acetyl-11-keto-b-Boswellic acid induces apoptosis in HL-60 and CCRF-CEM cells and inhibits topoisomerase I. J. Pharm. Exp. Therap. 288(2), 613-619.
- Lee, Y-W., Fang, Q-C., Wang, Z-G., Li, D-H., and Cook, C.E. (1991) Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers US Patent 5,064,823.
- Wildfeuer, A., Neu, I.S., Safayhi, H., Metzger, G., Wehrmann, M., Vogel, U., and Ammon, H.P.T. (1998) Effects of boswellic acids extracted from a herbal medicine on the biosynthesis of leukotrienes and the course of experimental autoimmune encepha-lomyelitis. Arzneim.-Forsch. Drug Res. 48(I), Nr 6, 668-674.
- Shao, Y., Ho, C-T., Chin, C-K., Badmaev, V., Ma, W., and Huang, M-T. (1998) Inhibitory activity of boswellic acids from Boswellia serrata against human leukemia HL-60 cells in culture. Planta Medica 64, 328-331.
- Jing, Y., Nakajo, S., Xia, L., Nakaya, K., Fang, Q., Waxman, S., and Han, R. (1999) Boswellic acid acetate induces differentiation and apoptosis in leukemia cell lines. Leukemia Research 23, 43-50.
- Gupta, V.N., Yadav, D.S., Jain, M.P., and Atal, C.K. (1987) Chemistry and Pharmacology of the gum resin of B. serrata. Indian Drugs 24(5), 221-231.
- Annual Report, Regional Research Laboratory (CSIR), Jammu, India (1987-88), pp 1-2.
- Singh, G.B. et al. (1992) New phytotherapeutic agent for treatment of arthritis and allied disorders with novel mode of action. IV and Int. Congress on Phytotherapy, Munich, Germany, Abstract SL 74.
- Booker, D-K. and Winking, M. (1997) Dtsch. Ärzteblatt 94, 1197 (cited in reference 18).
- Gupta, I., Parihar, A., Malhotra, P., Singh, G.B., L..udtke, R., Safayhi, H., and Ammon, H.P. (1997) Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Eur. J. Med. Res. 2(1), 37-43.
- Gupta, I., Gupta, V., Parihar, A., Gupta, S., L..udtke, R., Safayhi, H., and Ammon, H.P. (1998) Effects of Boswellia serrata gum resin in patients with bronchial asthma: results of a double blind, placebo-controlled, 6-week clinical study. Eur. J. Med. Res. 3(11), 511-514.
- Simmet, T. and Ammon, H.P.T. (1998) Use of boswellic acid for treating brain tumours. Patent WO 96/19212.
- Ammon, H.P.T. and Safayhi, H. (1997) Use of Boswellic acid and its derivatives for inhibiting normal and increased leucocytic elastase or plasmin activity. Patent WO 97/07796.
- Ammon, H.P.T., Safayhi, H.; and Singh, G.B. (1993) Use of pure boswellic acid. Patent EP 0552657.
- Weisman, B. (1999) Natural composition for treating bone or joint inflammation. US Patent 5,888,514.
- Taneja, S.C,; Sethi, V.K.; Dhar, K.L.; and Kapil, R.S. (1997) Boswellic acid compositions and preparation thereof. US Patent 5,629,351.
- Patwardhan, B. (1996) Method of treating musculoskeletal disease and a novel composition therefor. US Patent 5,494,668.
|
